Track topics on Twitter Track topics that are important to you
|Gazyva™||Chronic lymphocytic leukemia||
F. Hoffman-La Roche
|Vitekta™||HIV||Japan Tobacco/Gilead Sciences|
|Valchlor™||Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma||Ceptaris Therapeutics|
|Opsumit®||Pulmonary arterial hypertension||Actelion|
|NovoEight®||Factor VIII deficiency||Novo Nordisk|
Topics to Watch:
• Orphan Drugs – Roche subsidiary Genentech, and Biogen Idec launched Gazyva™, an anti-CD20 humanized IgF1 monoclonal antibody launched for the treatment of chronic lymphocytic leukemia (CLL), and Valchlor™, the first and only FDA-approved topical formulation of mechlorethamine for stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma, launched by Actelion.
• Alzheimer’s Disease – H.Lundbeck and Otsuka are developing Lu-AE58054, a selective antagonist of the 5-HT6 receptor which modulates neurotransmitter systems and is expressed in areas of the brain involved in cognition, entered phase III trials. If successful, worldwide sales of the drug are expected to reach $176 million in 2018.
• Scar Prevention – RXi Pharmaceuticals’ RXI-109 entered a phase II trial for the prevention of scar tissue formation. Scar prevention and reduction is an area of high unmet need, with no FDA-approved therapeutics available for post-operative scars.